

## Dissociation of AGAT, GAMT and SLC6A8 in CNS: Relevance to creatine deficiency syndromes

Olivier Braissant\*, Elidie Béard, Céline Torrent, Hugues Henry

Inborn Errors of metabolism, Clinical Chemistry Laboratory, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CH 1011 Lausanne, Switzerland

### ARTICLE INFO

#### Article history:

Received 18 June 2009

Revised 15 October 2009

Accepted 22 October 2009

Available online 29 October 2009

#### Keywords:

Creatine

Guanidinoacetate

Brain

Creatine Deficiency syndromes

Rat

### ABSTRACT

AGAT and GAMT, the two enzymes of the creatine synthesis pathway, are well expressed within CNS, suggesting autonomous brain creatine synthesis. This contradicts SLC6A8 deficiency, which causes creatine deficiency despite CNS expression of AGAT and GAMT. We hypothesized that AGAT and GAMT were not co-expressed by brain cells, and that guanidinoacetate must be transported between cells to allow creatine synthesis. We finely analyzed the cell-to-cell co-expression of AGAT, GAMT and SLC6A8 in various regions of rat CNS, and showed that in most structures, cells co-expressing AGAT + GAMT (equipped for autonomous creatine synthesis) were in low proportions (<20%). Using reaggregating brain cell cultures, we also showed that brain cells take up guanidinoacetate and convert it to creatine. Guanidinoacetate uptake was competed by creatine. This suggests that in most brain regions, guanidinoacetate is transported from AGAT- to GAMT-expressing cells through SLC6A8 to allow creatine synthesis, thereby explaining creatine deficiency in SLC6A8-deficient CNS.

© 2009 Elsevier Inc. All rights reserved.

### Introduction

In mammals, creatine (Cr) is taken from diet or synthesized by a two-step mechanism involving L-arginine:glycine amidinotransferase (AGAT) yielding guanidinoacetate (GAA) as intermediate, and guanidinoacetate methyltransferase (GAMT) converting GAA to Cr. Cells take up Cr through a specific transporter, SLC6A8 (Wyss and Kaddurah-Daouk, 2000).

Central nervous system (CNS) is the main organ affected in Cr deficiency syndromes caused by AGAT, GAMT or SLC6A8 deficiency (Stöckler et al., 1994; Schulze et al., 1997; Salomons et al., 2001; Item et al., 2001). These patients present neurological symptoms in infancy, including mental retardation and delays in speech acquisition. GAMT, and often SLC6A8 deficiencies, also cause epilepsy. Cr deficiencies are characterized by strongly decreased Cr levels in CNS, as measured by magnetic resonance spectroscopy (MRS). AGAT- and GAMT-deficient patients can be treated with oral Cr supplementation, while Cr supplementation of SLC6A8-deficient patients does not restore brain Cr (Stöckler et al., 2007; Schulze and Battini, 2007).

Brain cells synthesize Cr, as shown in organotypic cultures (Braissant et al., 2002; Almeida et al., 2006). *In vivo*, AGAT and GAMT are found in all brain cell types (neurons, astrocytes, oligodendrocytes); SLC6A8 is expressed in neurons and oligodendro-

cytes but not in astrocytes, and is present in microcapillary endothelial cells (MCEC) forming blood–brain barrier (BBB) (Braissant et al., 2001a; Ohtsuki et al., 2002; Schmidt et al., 2004; Tachikawa et al., 2004). Apart of BBB, astrocyte feet around MCEC are more and more recognized as true regulators of water and metabolite exchanges between periphery and CNS (Nedergaard et al., 2003). SLC6A8 absence from astrocytes suggested thus that BBB has a limited permeability for Cr (Braissant et al., 2001a). This is supported *in vivo*: the blood to brain Cr transport appears relatively inefficient in rodents (Ohtsuki et al., 2002; Perasso et al., 2003) and the replenishment of CNS Cr pools in AGAT- and GAMT-deficient patients supplemented with high doses of Cr is slow and only partial (Schulze and Battini, 2007). Moreover, Cr levels are normal in CSF of SLC6A8-deficient patients unable of Cr import from periphery, while they are strongly decreased in CSF of GAMT-deficient patients who can import Cr from periphery (Braissant and Henry, 2008).

These observations suggest that CNS depends more on autonomous Cr synthesis than on supply from periphery. This seems contradictory with SLC6A8-deficient patients who, despite AGAT and GAMT expression in CNS, show strongly decreased levels of brain Cr. We hypothesized that the brain cell-to-cell AGAT, GAMT and SLC6A8 expression pattern might explain this contradiction: AGAT and GAMT, which can be found in every CNS cell types, might not be co-expressed within the same cells. That would also imply that GAA must be transported between brain cells for Cr synthesis to occur. This work aimed at dissecting the cell-to-cell co-expression of AGAT, GAMT and SLC6A8 within various regions of rat CNS. Moreover, brain cell GAA uptake and its conversion to Cr were analyzed by tandem mass

\* Corresponding author. Fax: +41 21 314 35 46.

E-mail address: [Olivier.Braissant@chuv.ch](mailto:Olivier.Braissant@chuv.ch) (O. Braissant).

Available online on ScienceDirect ([www.sciencedirect.com](http://www.sciencedirect.com)).

spectrometry in reaggregated brain cell primary cultures, which synthesize Cr and express AGAT, GAMT and SLC6A8 as CNS *in vivo* (Braissant et al., 2008).

## Materials and methods

### Preparation of adult rat brains

Animal procedures were in compliance with the directives of the Swiss Academy of Medical Science. Adult rats (Sprague–Dawley, 300 g, Harlan, Netherlands) were sacrificed by decapitation. Their brain was extracted within 2 min, rinsed in diethylpyrocarbonate-treated PBS, and immediately embedded in tissue freezing medium (Tissue-Tek, Sakura Finetek, Netherlands), frozen in liquid nitrogen-cooled isopentane and stored at  $-80^{\circ}\text{C}$ .

### In situ hybridization and immunohistochemistry

AGAT, GAMT and SLC6A8 expression was analyzed within various representative regions of the rat brain (Fig. 1 and Supplementary Table 1) by *in situ* hybridization (ISH) coupled to immunohistochemistry, allowing the detection of both mRNA and protein for AGAT, GAMT and SLC6A8 genes. To achieve this, specific RNA probes and antibodies were applied to rat brain cryosections (12  $\mu\text{m}$  thick). ISH was performed by hybridizing digoxigenin-labeled antisense and


sense riboprobes specific for rat AGAT, GAMT and SLC6A8 as described in details (Braissant et al., 2001a). Sections were stained with alkaline-phosphatase using nitroblue-tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate (blue signal). After staining, sections were dehydrated. The hybridization specificity was ascertained by the negative staining of ISH sense control probes-hybridized sections for AGAT, GAMT and SLC6A8 (data not shown). Sense probes-hybridized sections were mounted (Eukitt, O.Kindler, Germany). Antisense probes-hybridized sections were processed for immunohistochemistry as described in details (Braissant, 2004), using specific anti-AGAT, -GAMT and -SLC6A8 rabbit polyclonal antibodies already characterized (Braissant et al., 2005), or alternatively anti-glial fibrillary acidic protein (GFAP) or anti-NeuN mouse monoclonal antibodies (Chemicon International). Sections were stained using horse radish peroxidase, the Histostain-Plus kit (Zymed Laboratories) and aminoethyl-carbazole/ $\text{H}_2\text{O}_2$  (red signal).

The double-stained sections (ISH blue, immunohistochemistry red) were mounted in glycerol. AGAT, GAMT and SLC6A8 patterns were considered specific and validated by the excellent correlation, in all CNS regions, between signals observed by ISH (mRNA) and immunohistochemistry (protein), the negative signals observed with ISH sense probes, and the absence of labeling in immunohistochemical controls without primary antibodies or in presence of pre-immune serum (data not shown, and Braissant et al., 2005). The ISH protocol sensitivity, which can detect as low as 15 transcripts per cell, has been described elsewhere (Braissant et al., 2001b; Braissant, 2004).

### Histological analysis and cell counting

Sections were observed on an Olympus BX50 microscope equipped with a ColorView-II camera (Olympus Optical, Japan). Brain structures were identified according to Paxinos and Watson (1986) (Supplementary Table 1). In each brain structure, cells were counted within a square surface of  $200\ \mu\text{m} \times 160\ \mu\text{m}$  (12  $\mu\text{m}$  thick cryosections), except for CA3 pyramids and dentate gyrus granular neurons (hippocampus), and for Purkinje neurons (cerebellum), where cells were counted along 200  $\mu\text{m}$  (hippocampus) or 500  $\mu\text{m}$  (Purkinje neurons) of these linear structures. Cell counting was achieved with the help of the CellF software (Olympus). The average number of cells counted per brain and per co-labeling experiment is indicated in Supplementary Table 1. While AGAT, GAMT and SLC6A8 proteins can be localized far from soma (e.g.: cell processes), they are also present, when expressed, in soma (AGAT and GAMT) or at its surface (SLC6A8) (Tachikawa et al., 2004; Braissant et al., 2008; Tachikawa et al., 2008). Therefore, to be coherent with ISH counting (mRNA, essentially localized around nucleus), brain cells were counted positive for AGAT, GAMT or SLC6A8 proteins only if their soma showed the immunohistochemistry signal.

The 3 different “2 by 2” combinations (AGAT + GAMT; AGAT + SLC6A8; GAMT + SLC6A8) were unraveled in each brain analyzed ( $n=3$ ; 2 females, 1 male). For each combination, mRNA no. 1 was revealed by ISH coupled to immunohistochemistry for protein no. 2, followed on adjacent section by ISH detection of mRNA no. 2 coupled to immunohistochemistry for protein no. 1. Particular care was taken to consider identical cells on adjacent sections. All combinations were repeated twice, allowing, for each brain, a total of 4 labeling “2 by 2” of each combinations of the 3 genes (12 adjacent sections covering 144  $\mu\text{m}$  depth of brain parenchyma). The series of (co-)labeling, distributed among the three rat brains used, were designed to allow the observation of the largest neuronal soma, by the continuous observation of each of the three genes through a depth of 96  $\mu\text{m}$  (i.e.: 8 adjacent sections). With each “2 by 2” combination and for each brain structure, the cell proportions with no expression of genes 1 or 2, expression of gene 1 only, expression of gene 2 only, or co-expression of genes 1 and 2, were obtained (= values  $x_i$ , also defined in Supplementary Tables 2 and 3). Each combination of “2 by 2” co-



**Fig. 1.** Rat brain structures analyzed for AGAT, GAMT and SLC6A8 co-expression. (A) 10 different structures of the rat brain were analyzed: Cortex (layer V, Cx); caudate putamen (CP); hippocampus (CA3 and dentate gyrus neurons, DG); hypothalamus (ventromedial nucleus, VMH); inferior colliculus (IC); pons (parvocellular reticular nucleus, PCRT); cerebellum (molecular layer, Mol; Purkinje neurons, Pur; and deep medial nucleus, Med) (sagittal view of rat brain adapted from <http://www.brain-map.org>; lateral level for rat brain: 1.20 mm). (B) The proportions of cells (co-) expressing AGAT alone (y2), GAMT alone (y3), SLC6A8 alone (y4), AGAT + GAMT (y5), AGAT + SLC6A8 (y6), GAMT + SLC6A8 (y7), AGAT + GAMT + SLC6A8 (y8), or none (y1), were determined in each brain structures (see also Supplementary Tables 2–4).

labeling ( $n=4$ ) gave extremely coherent results (see standard deviations in [Supplementary Table 3](#)). Thus, for each gene in each couple of genes, in each of the 10 different brain regions analyzed from 3 different rat brains, mRNA and protein data gave identical proportions: When a specific mRNA was detected on one slice, its respective protein was always detected also in the same cell on the adjacent slice, and no presentation of mRNA without its respective protein occurred. Conversely, when a specific protein was detected on one slice, its respective mRNA was always detected also in the same cell on the adjacent slice, and no presentation of protein without its respective mRNA occurred. Thus, these very coherent data between mRNA (perinuclear region) and protein (considered only in the cell soma) validated the gene expression observation in the brain cell soma as truly representative of expression in the whole brain cells.

This allowed then the determination of AGAT, GAMT and SLC6A8 (co-)expression patterns taken “3 by 3” (AGAT + GAMT + SLC6A8 co-expression; see below).

The determination of the “3 by 3” AGAT + GAMT + SLC6A8 co-expression proportions (= values  $y_j$ , also defined in [Fig. 1B](#) and [Supplementary Table 2](#)) was obtained using two different approaches:

The first consisted in determining the smallest intervals containing each of the  $y_1$  to  $y_8$  “3 by 3” expression proportions. To achieve this, we determined  $x_i$  as the lowest  $x_{1-12}$  experimental measure in each brain structure. We chose one of the two  $y_j$  unknowns giving  $x_i$  as sum, to express all the other  $y_1$  to  $y_8$  unknowns, allowing finally the determination of the smallest intervals fitting for  $y_1$  to  $y_8$  (see their complete determination, illustrated for dentate gyrus, in [Supplementary Table 3](#)). These intervals are presented in the left columns of [Figs. 3A–C](#) (“experimental”).

The second was based on the hypothesis, true or not, that AGAT, GAMT and SLC6A8 might be expressed independent of each other in brain cells, both at transcriptional and translational levels.  $y_1$  to  $y_8$  were calculated, in each brain structure, by developing, based on [Fig. 1](#) and [Supplementary Table 2](#), the following equations, exemplified here for  $y_2$  (AGAT only) :

$$y_2 = x_2 - y_6 = x_2 - [y_6 / (y_2 + y_6) * (y_2 + y_6)]. \quad (1)$$

Then, if (and only if) AGAT, GAMT and SLC6A8 genes are expressed independent of each other in the brain, both at transcriptional and translational levels :

$$y_6 / (y_2 + y_6) = (y_6 + y_8) / (y_2 + y_6 + y_5 + y_8). \quad (2)$$

After replacement of “ $y_6 / (y_2 + y_6)$ ” in (1) :

$$y_2 = x_2 - [(y_6 + y_8) / (y_2 + y_6 + y_5 + y_8) * (y_2 + y_6)] \\ = x_2 - [x_8 / (x_8 + x_6) * x_2]. \quad (3)$$

For each  $y_j$ , 3 different (but equivalent) equations can be developed, the 2 equations remaining for  $y_2$  being:

$$y_2 = x_6 - y_5 = x_6 - [x_{10} / (x_{10} + x_9) * x_6], \quad (4)$$

$$y_2 = x_9 - y_1 = x_9 - [x_1 / (x_1 + x_2) * x_9], \quad (5)$$

By analogy, the same calculation procedure was applied to  $y_1$  and  $y_3$  to  $y_8$  (see their complete calculation, illustrated for dentate gyrus, in [Supplementary Table 4](#)).  $y_j$  values for each brain structure using this second method is presented in the right columns of [Figs. 3A–C](#) (“calculated”).

#### Reaggregated brain cell cultures

Reaggregated brain cell primary cultures were prepared from mechanically dissociated telencephalon of 16-day rat embryos, grown in serum-free, Cr-free, chemically-defined medium ([Braissant et al.](#),

2008). These cultures develop with neurons, astrocytes and oligodendrocytes organized in a 3D network acquiring a tissue-specific pattern resembling that of the *in vivo* brain, and are therefore considered as organotypic brain cell cultures ([Honegger and Monnet-Tschudi, 2001; Cagnon and Braissant, 2007](#)). These cultures express AGAT, GAMT and SLC6A8 in the same cells as *in vivo* brain and synthesize their own Cr, suggesting that they behave as *in vivo* CNS for Cr synthesis and transport ([Braissant et al., 2008](#)). Brain cell aggregates were grown for 13 days *in vitro* (DIV), then exposed for 12 h or 24 h to various concentrations of GAA (GAA or  $^{13}\text{C}_2$ -GAA; 200, 600 or 1000  $\mu\text{M}$ ) and/or Cr (Cr or  $^{13}\text{C}$ -Cr; 200 or 1000  $\mu\text{M}$ ). Aggregates were harvested at DIV13.5 (12 h exposure) or DIV14 (24 h exposure), washed three times with ice-cold PBS, frozen in liquid nitrogen, and stored at  $-80^\circ\text{C}$ .

#### Creatine and guanidinoacetate determination, and GAMT activity

Brain cell aggregates were homogenized in  $\text{H}_2\text{O}$  at  $4^\circ\text{C}$  using a FastPrep Cell Disrupter (Qbiogene, France) and centrifuged (10,000g, 5 min,  $4^\circ\text{C}$ ). The supernatant was used to measure Cr and GAA by electrospray tandem mass spectrometry, as described in details ([Braissant et al., 2008](#)).  $\text{D}_3$ -Cr (CDN Isotopes, Canada) and  $^{13}\text{C}_2$ -GAA (Dr Herman J ten Brink, Amsterdam, Netherlands) were used as internal standards. Cr and GAA were purified by micro solid phase extraction (Oasis MCX  $\mu\text{Elution}$  Plate, Waters, MA USA). Separation of Cr and GAA was achieved at  $30^\circ\text{C}$  using an Atlantis HILIC silica  $2.1 \times 50$  mm  $3 \mu\text{m}$  (Waters, MA USA). The column effluent was monitored using a Triple Quadrupole TSQ Quantum Discovery (Thermo Scientific, CA USA). The instrument was equipped with an electrospray interface and was controlled by the Xcalibur software (Thermo Scientific, CA USA). Samples were analyzed in positive ionization mode operating in a cone voltage of 4 kV. The tandem mass spectrometer was programmed using the selected reaction monitoring mode (SRM) to allow the  $[\text{MH}^+]$  ions of Cr and GAA respectively at  $m/z$  132 and 118 and that of the internal standards  $\text{D}_3$ -Cr and  $^{13}\text{C}_2$ -GAA at  $m/z$  135 and 120 to pass through the first quadrupole (Q1) and into the collision cell (Q2). The daughter ions for Cr and GAA are of  $m/z$  90 and 76 respectively, and of  $m/z$  93 and 78 for  $\text{D}_3$ -Cr and  $^{13}\text{C}_2$ -GAA respectively. Calibration curves were computed using the peak area ratio of analytes and internal standards.

For GAA uptake, brain cell aggregates were incubated for 12 h or 24 h with 200 or 600  $\mu\text{M}$  GAA. Intracellular GAA was measured as described above using SRM with the transition of  $m/z$  118 to  $m/z$  76. For Cr uptake, brain cell aggregates were incubated for 12 h in presence of 200  $\mu\text{M}$   $^{13}\text{C}$ -Cr (Cambridge Isotope Laboratories, MA USA). Intracellular  $^{13}\text{C}$ -Cr was measured as above using SRM with transition of  $m/z$  133 to  $m/z$  91. The relative abundance of  $m/z$  133 calculated at a ratio of 3.8 % of endogenous Cr was deduced from the measured transported  $^{13}\text{C}$ -Cr. Uptakes of GAA and  $^{13}\text{C}$ -Cr (12 h incubation, 200  $\mu\text{M}$ ) were competed by 5-fold excess (1 mM) of Cr and GAA, respectively.

GAMT activity of brain cell aggregates *in vivo* was accessed by the synthesis of endogenous  $^{13}\text{C}_2$ -Cr when incubated with  $^{13}\text{C}_2$ -GAA (12 h incubation, 200  $\mu\text{M}$   $^{13}\text{C}_2$ -GAA). Newly synthesized  $^{13}\text{C}_2$ -Cr was measured using SRM with transition of  $m/z$  134 to  $m/z$  92.

#### Statistical analysis

The statistical significance of intracellular GAA and Cr variations ([Fig. 6](#)) was evaluated by Student's *t* test.  $p < 0.05$  was considered significant. Data were expressed as mean  $\pm$  standard deviation.

#### Results

Using ISH coupled to immunohistochemistry, the 3 different “2 by 2” combinations (AGAT + GAMT; AGAT + SLC6A8; GAMT + SLC6A8) were unraveled on adjacent sections of the rat brain. For each



combination, mRNA no. 1 was revealed by ISH coupled to immunohistochemistry for protein no. 2, followed on adjacent section by ISH detection of mRNA no. 2 coupled to immunohistochemistry for protein no. 1. Particular care was taken to consider identical cells on adjacent sections. When a specific mRNA was detected on one slice, its respective protein was always detected also in the same cell on the adjacent slice, and no presentation of mRNA without its respective protein occurred. Conversely, when a specific protein was detected on one slice, its respective mRNA was always detected also in the same cell on the adjacent slice, and no presentation of protein without its respective mRNA occurred.

*AGAT, GAMT and SLC6A8 are expressed independent of each other in rat CNS*

Two different approaches were used to determine the “3 by 3” AGAT + GAMT + SLC6A8 co-expression proportions ( $=y_j$ ; as also defined in Fig. 1B and Supplementary Figure 2) of brain cells. The 1st was the simple estimation of the minimal interval containing each  $y_j$  proportion based on the direct measure ( $=$  cell counting) of the “2 by 2” AGAT, GAMT and SLC6A8 co-expression proportions ( $=x_i$ ; as also defined in Supplementary Figure 2). The 2nd was based on the hypothesis, true or not, that AGAT, GAMT and SLC6A8 might be expressed independent of each other in brain cells, both at the level of transcription and translation. This hypothesis allowed to calculate the “3 by 3” expression proportions ( $y_j$ ) from the “2 by 2” expression proportions ( $x_i$ ). Two strikingly identical expression patterns were found using these two independent approaches (Figs. 3A–C), in each brain structure analyzed. As the 1st approach is a true measure of the “3 by 3” expression proportions, and as the 2nd approach is valid only if AGAT, GAMT and SLC6A8 are expressed independent of each other, we conclude that in rat CNS, AGAT, GAMT and SLC6A8 genes are expressed independent of each other, both at the level of transcription and translation.

Four different AGAT, GAMT and SLC6A8 co-expression patterns were found depending of brain structures (Figs. 2 and 3). Figs. 2–5, as well as Supplementary Tables 1, 3 and 4, show the data from one representative adult rat brain, the same patterns having been obtained in two other adult rat brains.

*Cortex, inferior colliculus and cerebellum (molecular layer and deep medial cerebellar nucleus)*

In cortex (layer V), 31% of brain cells were silent for AGAT, GAMT or SLC6A8 (Figs. 2B, E, F and 3A). Cells expressing AGAT, GAMT or SLC6A8 alone were 15%, 14% and 14% respectively. Cells co-expressing AGAT and GAMT (but not SLC6A8) were 8%, cells expressing AGAT and SLC6A8 (but not GAMT) were 7%, and cells co-expressing GAMT and SLC6A8 (but not AGAT) were 8%. Finally, cells co-expressing AGAT, GAMT and SLC6A8 were 4%. Thus, in cortex, cells silent for the three genes were 31%, cells equipped for autonomous Cr synthesis (AGAT + GAMT) were 12%, and cells equipped for Cr synthesis from imported GAA (SLC6A8 + GAMT) were 12%. Cells with only SLC6A8 (“users” of Cr, but not participating to its synthesis) were 14%.

Similar expression patterns were found in inferior colliculus as well as in cerebellar molecular layer and deep medial nucleus (Fig. 3A). In inferior colliculus, cells silent for the three genes were 33%, cells equipped for autonomous Cr synthesis were 14%, and cells equipped for Cr synthesis from imported GAA were 16%. Cells with only SLC6A8 were 12%. In molecular layer of cerebellum, cells silent for the three genes were 32%, cells equipped for autonomous Cr synthesis were 18%, and cells equipped for Cr synthesis from imported GAA were 17%. Cells with only SLC6A8 were 9%. In deep medial nucleus of cerebellum, cells silent for the three genes were 21%, cells equipped for autonomous Cr synthesis were 22%, and cells equipped for Cr synthesis from imported GAA were 26%. Cells with only SLC6A8 were 11%.

*Hippocampus (CA3 and dentate gyrus granular neurons) and hypothalamus*

Hippocampus (neurons of CA3 layer and dentate gyrus) and ventromedial nucleus of hypothalamus presented similar patterns (Figs. 2C, D and 3B). In hippocampal CA3 layer, 40% of neurons co-expressed AGAT, GAMT and SLC6A8, 20% being silent for the three genes. 47% of cells were equipped for autonomous Cr synthesis, cells equipped for Cr synthesis from imported GAA were 49%, and cells with SLC6A8 only were 6%. In granular neurons of dentate gyrus, 32% of cells co-expressed AGAT, GAMT and SLC6A8, 35% being silent for the three genes. 38% of cells were equipped for autonomous Cr synthesis, cells equipped for Cr synthesis from imported GAA were 37%, and cells with SLC6A8 only were 5%. In hypothalamic ventromedial nucleus, 29% of cells co-expressed AGAT, GAMT and SLC6A8, 30% being silent for the three genes. 37% of cells were equipped for autonomous Cr synthesis, cells equipped for Cr synthesis from imported GAA were 37%, and cells with SLC6A8 only were 4%.

*Purkinje neurons*


37% of Purkinje neurons co-expressed AGAT, GAMT and SLC6A8, 9% only being silent for the three genes. 61% of Purkinje neurons were equipped for autonomous Cr synthesis, cells equipped for Cr synthesis from imported GAA were 44%, and cells with SLC6A8 only were 5% (Fig. 3B).

*Caudate putamen and pons (parvocellular reticular nucleus)*

Caudate putamen and parvocellular reticular nucleus of pons showed very peculiar patterns (Figs. 2A and 3C). In caudate putamen, 50% of cells were silent for AGAT, GAMT or SLC6A8, and 43% expressed GAMT only. Cells equipped for autonomous Cr synthesis were 1%, cells equipped for Cr synthesis from imported GAA were 1%, and cells with SLC6A8 only were 2%. In parvocellular reticular nucleus of pons, 44% of cells were silent for AGAT, GAMT or SLC6A8, and 37% expressed AGAT only. Cells equipped for autonomous Cr synthesis were 7%, cells equipped for Cr synthesis from imported GAA were 5%, and cells with SLC6A8 only were 4%.

*Proportions of neurons and astrocytes expressing AGAT, GAMT and SLC6A8 in cortex*

We analyzed within layer V of cortex whether AGAT and GAMT were homogeneously expressed between neurons and glia. This was achieved by ISH for AGAT, GAMT or SLC6A8 mRNAs, coupled to immunohistochemistry for the neuronal marker NeuN or the astrocytic marker GFAP (Fig. 4). The abovementioned cell counting method was applied to determine the proportion of specific cell types expressing AGAT, GAMT or SLC6A8 (Fig. 5A). We showed that only 22% of NeuN-positive neurons were positive for AGAT, while 48% were positive for GAMT. In contrast, 55% of GFAP-positive astrocytes were positive for AGAT, while only 21% were positive for GAMT. 27% of NeuN-positive neurons expressed SLC6A8, while, as expected, no astrocyte was found expressing SLC6A8. As AGAT, GAMT and SLC6A8 are expressed independent of each other (see above and Fig. 3), applying the calculation method described in Methods and Supplementary Tables 2 to 4 allowed to reconstitute the differential “3 by 3” AGAT + GAMT + SLC6A8 co-expression in cortical neurons and astrocytes (Fig. 5B). We show in particular that important proportions of both neurons (25%) and astrocytes (35%) were silent for the three genes. Based on the 1:0.4 ratio of neurons versus astrocytes in the rat cortex (Nedergaard et al., 2003), we could reconstitute the cumulative proportions of cortical neurons and astrocytes co-expressing AGAT, GAMT and SLC6A8, which fitted remarkably well with the direct measure of expression ranges presented in Fig. 3A (Fig. 5C). The slight



**Fig. 2.** Co-expression of AGAT, GAMT and SLC6A8 in the rat brain. *In situ* hybridization (mRNA, blue signal) coupled to immunohistochemistry (protein, red signal), showing “2 by 2” co-expression of (A) AGAT mRNA and GAMT protein in pons, (B) GAMT mRNA and AGAT protein in layer V of cortex, (C) AGAT mRNA and SLC6A8 protein in hypothalamus, (D) SLC6A8 mRNA and AGAT protein in CA3 neurons, (E) GAMT mRNA and SLC6A8 protein in layer V of cortex, and (F) SLC6A8 mRNA and GAMT protein in layer V of cortex. Examples of cells without any labeling are indicated by empty arrows; examples of cells with gene 1 mRNA expression only are indicated by blue arrows; examples of cells with gene 2 protein expression only are indicated by red arrows; examples of cells with co-labeling for gene 1 mRNA and gene 2 protein are indicated by purple arrows. Bar: 50  $\mu$ m.

variations between both patterns are likely due to other cell types present in lower proportions within cortex (oligodendrocytes, microglia), which were not evaluated here.

#### Brains cells take up guanidinoacetate and convert it to creatine

As most rat brain structures showed a high proportion of cellular dissociation between AGAT- and GAMT-expressing cells, we hypothesized that brain cells were able to import GAA, and convert it to Cr. Using rat brain cell primary cultures in aggregates, we first demonstrated by tandem mass spectrometry that brain cells can import GAA (Fig. 6A). Exposure up to 200  $\mu$ M GAA for 12 h did not

disturb the endogenous Cr synthesis pathway, which occurs in this system as in CNS *in vivo* (Braissant et al., 2008); a higher GAA concentration (600  $\mu$ M) was toxic to brain cells, as shown by the 30% decrease in intracellular Cr (Fig. 6A), as well as by axonal growth impairment and induction of apoptosis (data not shown). 24 h GAA exposure had the same effects (data not shown). We further showed that imported GAA could be converted to Cr, by exposing brain cell aggregates to  $^{13}$ C stable isotope-labelled  $^{13}$ C<sub>2</sub>-GAA, and measuring intracellular  $^{13}$ C<sub>2</sub>-Cr. After 12 h exposure to 200  $\mu$ M  $^{13}$ C<sub>2</sub>-GAA, 29% of imported  $^{13}$ C<sub>2</sub>-GAA was converted to  $^{13}$ C<sub>2</sub>-Cr (Fig. 6B). Finally, we showed that 1000  $\mu$ M Cr completely competed GAA uptake by brain cells (200  $\mu$ M GAA exposure), with the same efficiency as 1000  $\mu$ M



GAA competed Cr uptake (200  $\mu\text{M}$   $^{13}\text{C}$ -Cr exposure, to avoid influence of the endogenous Cr synthesis pathway) (Fig. 6C).


Discussion

Brain AGAT, GAMT and SLC6A8 are expressed independent of each other

This work demonstrates that AGAT, GAMT and SLC6A8 are expressed independent of each other in CNS, at the level of transcription and translation. Cr exerts a negative pre-translational feedback on AGAT regulation in kidney (McGuire et al., 1984). Brain appears to behave differently, where Cr rather alters AGAT enzymatic activity (Braissant et al., 2008). Human muscle behave similarly, where Cr does not influence SLC6A8 expression (Tarnopolsky et al., 2003). Thus, brain AGAT, GAMT and SLC6A8 expression does not seem influenced by their substrate or reaction products, probably allowing CNS to be permanently equipped with Cr synthesis and transport machineries, something crucial knowing that Cr is essential in CNS development and functions (Braissant and Henry, 2008; Andres et al., 2008).

Dissociation of AGAT and GAMT, and GAA uptake by brain cells: Relevance to Cr deficiency syndromes

Brain Cr was thought to come principally from periphery through BBB (Wyss and Kaddurah-Daouk, 2000). However, mammalian CNS synthesizes Cr and express AGAT and GAMT in every cell types (Pisano et al., 1963; Braissant et al., 2001a; Schmidt et al., 2004; Tachikawa et al., 2004). SLC6A8 is expressed in CNS, but only by neurons and oligodendrocytes. The SLC6A8 absence from astrocytes (particularly astrocyte feet lining MCEC; Braissant et al., 2001a; Ohtsuki et al., 2002; Tachikawa et al., 2004) made us suggest that BBB has a limited permeability for Cr, and that CNS depends more on autonomous Cr synthesis than on supply from periphery (Braissant et al., 2007; Braissant and Henry, 2008). Brain autonomous Cr synthesis seems contradictory with *in vivo* characteristics of SLC6A8 deficiency, which, despite normal CNS expression of AGAT and GAMT, shows no, or very low levels of, brain Cr by MRS, as in AGAT and GAMT deficiencies. We hypothesized that this apparent contradiction might be explained by brain patterns of



**Fig. 3.** Co-expression of AGAT, GAMT and SLC6A8 in the different structures of the rat brain. (A) cortex, inferior colliculus and cerebellum (molecular layer and deep medial nucleus). (B) hippocampus (CA3 and dentate gyrus), hypothalamus (ventromedial nucleus) and cerebellum (Purkinje neurons). (C): caudate putamen and pons (paraventricular nucleus). The percentage of cells (co-)expressing AGAT alone, GAMT alone, SLC6A8 alone, AGAT + GAMT, AGAT + SLC6A8, GAMT + SLC6A8, AGAT + GAMT + SLC6A8, or none, is indicated, for both methods used (experimental and calculated) to estimate these proportions (see also Fig. 2 for an illustration of the co-labeling used). For the experimental measure of co-expression proportions (left column), the ranges between minimal and maximal proportions are represented (open white rectangle). For the calculated proportions (right column), means  $\pm$  standard deviations ( $n=3$ ) are represented.





Fig. 3 (continued).



**Fig. 4.** Expression of AGAT, GAMT and SLC6A8 in cortical neurons and astrocytes. *In situ* hybridization for AGAT (A, D), GAMT (B, E) and SLC6A8 (C, F) mRNAs (blue signal), coupled to immunohistochemistry for neuronal (NeuN; A–C) and astrocytic (GFAP; D–F) markers respectively (red signal). Examples of neurons and astrocytes without co-labelling for AGAT, GAMT or SLC6A8 are indicated by red arrows, while examples of neurons and astrocytes with co-labelling for AGAT, GAMT or SLC6A8 are indicated by purple arrows. Bar: 50  $\mu$ m.


AGAT, GAMT and SLC6A8, which might be expressed in a dissociated way (Braissant and Henry, 2008).

This work demonstrates that in many brain structures, including those usually observed by MRS, cells fully equipped for Cr synthesis (co-expressing AGAT + GAMT) are <20% (cortex: 12%, striatum: 1%), and that a higher proportion of cells expresses AGAT without GAMT, or GAMT without AGAT. This suggested that for Cr synthesis to occur, GAA must be transported from AGAT- to GAMT-expressing cells. If GAA is transported by SLC6A8 (see below), it would explain the absence of Cr measured by MRS in CNS of SLC6A8-deficient patients. This recently proposed model (Braissant and Henry, 2008) is also supported *in vivo* by the attempt to treat SLC6A8-deficient patients with arginine to stimulate replenishment of their cerebral Cr pool by brain endogenous synthesis, which failed to increase CNS Cr (Fons et al., 2008). Thus, according to the above-mentioned hypothesis, in human brain also, GAA must be transported from

AGAT- to GAMT-expressing cells, through SLC6A8, for Cr synthesis to occur.

Whilst in most regions of AGAT- and GAMT-deficient brain, the MRS measure of Cr should show an absence or strong decrease of Cr (partly due to the lack of brain autonomous Cr synthesis), the situation may be more contrasted in SLC6A8 deficiency. Indeed, the MRS Cr measure is usually performed in cortical areas and basal ganglia (striatum), where SLC6A8-deficient patients present an absence or strong decrease of Cr (DeGrauw et al., 2002) (excepted for females heterozygous for SLC6A8 mutation, who usually present a milder cerebral Cr deficiency, as SLC6A8 deficiency is an X-linked disorder). If AGAT, GAMT and SLC6A8 patterns, as described here in rat CNS, are also true in human, a normal or only attenuated Cr peak should be detected in brain regions of SLC6A8-deficient patients presenting high proportions of cells co-expressing AGAT + GAMT, like hippocampus, hypothalamus or Purkinje cells.






**Fig. 5.** Proportions of neurons and astrocytes expressing AGAT, GAMT and SLC6A8, respectively, within layer V of cortex. Cell counting as described in [Materials and methods](#), from co-labeling experiments as shown in [Fig. 4](#) (ISH for AGAT, GAMT or SLC6A8, coupled to immunohistochemistry for NeuN or GFAP to identify neurons and astrocytes, respectively). Data from a representative adult rat cortex; 6 adjacent sections observed for each co-labeling experiment; total number of NeuN-positive neurons: 441; total number of GFAP-positive astrocytes: 337. The cell percentages are based on the cumulative counting of the 6 adjacent sections, for each co-labeling experiment. (A) Proportions of cortical neurons, respectively astrocytes, expressing AGAT, GAMT or SLC6A8; (B) reconstitution of the “3 by 3” AGAT, GAMT and SLC6A8 expression pattern within cortical neurons and astrocytes; (C) reconstitution of the cumulative, neuronal and astrocytic, “3 by 3” AGAT, GAMT and SLC6A8 expression pattern, based on the ratio of 1 neuron per 0.4 astrocyte ([Nedergaard et al., 2003](#)). Measured ranges between minimal and maximal proportions (taken from [Fig. 3A](#)) are shown in white rectangles, for comparison.

The striking patterns found for AGAT in pons and GAMT in caudate putamen are difficult to interpret. However, the GAMT-only expression of caudate putamen may fit with GAMT deficiency, which impairs striatum development ([Von Figura et al., 2001](#)).

#### GAA uptake by brain cells, and conversion to Cr

GAA competes for Cr uptake by SLC6A8 ([Ohtsuki et al., 2002](#)). Our work brings the first evidence that cells of brain parenchyma



**Fig. 6.** Uptake of guanidinoacetate by brain cells, and conversion to creatine. Measure of intracellular GAA and Cr within brain cell 3D cultures (DIV13) by tandem mass spectrometry, after 12 h of exposure to GAA (GAA or  $^{13}\text{C}_2$ -GAA) and/or Cr (Cr or  $^{13}\text{C}$ -Cr). (A) GAA Uptake by brain cells, and influence on endogenous Cr synthesis pathway. Cultures exposed for 12 h to 200 and 600  $\mu\text{M}$  GAA, respectively, and measure of intracellular GAA and Cr. (B) Conversion of GAA taken up by brain cells to Cr. Cultures exposed for 12 h to 200  $\mu\text{M}$   $^{13}\text{C}_2$ -GAA, and measure of intracellular  $^{13}\text{C}_2$ -GAA and  $^{13}\text{C}$ -Cr. (C) Competition of GAA uptake by Cr, respectively of Cr uptake by GAA, in brain cells. Cultures exposed 12 h to 200  $\mu\text{M}$  GAA ( $\pm$  competition with 1000  $\mu\text{M}$  Cr), respectively, 200  $\mu\text{M}$   $^{13}\text{C}$ -Cr ( $\pm$  competition with 1000  $\mu\text{M}$  GAA), and measure of intracellular GAA, respectively  $^{13}\text{C}$ -Cr. A–C show representative experiments, with mean  $\pm$  standard deviations for each point of measure. Significant increase in GAA, respectively decrease in Cr (A) are indicated, as compared to control conditions (200  $\mu\text{M}$  GAA), respectively, to control conditions and 200  $\mu\text{M}$  GAA (600  $\mu\text{M}$  GAA). Student's *t* test; *n* = 3; NS: not significant; \*\**p* < 0.01; \*\*\**p* < 0.001).

(neurons, astrocytes, oligodendrocytes) can take up GAA. GAA uptake was completely competed by 5-fold excess Cr, as efficiently as Cr uptake was competed by 5-fold excess GAA. This strongly suggests that GAA is taken up by brain cells through the same transporter as Cr: SLC6A8. This is in good agreement with SLC6A8 overexpression studies in HEK293 cells and *Xenopus* oocytes ([Tachikawa et al., 2008](#)). Finally, using  $^{13}\text{C}_2$ -GAA, our work is the first to demonstrate that GAA taken up by brain cells is readily converted to Cr, in line with our hypothesis that for Cr synthesis to occur in CNS, GAA must be transported from AGAT- to GAMT-expressing cells. The low proportion of GAA conversion to Cr (29%) was due to the diluting effect of endogenous Cr synthesis pathway. One important question remaining to elucidate is how GAA can leave AGAT-expressing cells to be imported by GAMT-expressing cells through SLC6A8.

A recent work demonstrated GAA uptake by TR-CSFB cells (blood–CSF barrier model) and isolated choroid plexus *in vitro*, probably by SLC6A8, but concluded that due to GAA:Cr ratio in CSF (1:1000; 0.015–0.560  $\mu\text{M}$  versus 17–90  $\mu\text{M}$  in human; [Braissant and Henry, 2008](#)), SLC6A8 was unlikely to transport GAA in choroid plexus *in vivo* ([Tachikawa et al., 2008](#)). Cr and GAA concentrations are much higher in brain parenchyma (5–6 mM and 0.9–1.6 mM in human, respectively), but nothing is known on their concentrations in extracellular fluid. In rat brain parenchyma, Cr was measured at 8.5 mM ([Renema et al., 2003](#)), and we measured GAA at levels 5- to 10-fold lower than Cr in rat brain cell organotypic cultures ([Braissant et al., 2008](#); and this study). We may thus extrapolate levels of GAA in rat brain parenchyma at

0.85–1.7 mM, comparable to human. 200  $\mu$ M GAA, as used in this study, may thus be relevant in CNS extracellular fluid, at least locally, in vicinity of GAA transfer from AGAT- to GAMT-expressing cells.

#### *AGAT and GAMT dissociation, as well as Cr and GAA uptake in CNS: A role for neuromodulation?*

Dissociation of AGAT and GAMT activities between different brain cells may appear expensive for CNS in terms of both the energy and machinery needed to transfer GAA, and GAA toxicity to neurons if released in the extracellular space at too high concentrations. Cr is exocytotically released from central neurons (Almeida et al., 2006) and acts as partial agonist on central GABA<sub>A</sub> post-synaptic receptors (Koga et al., 2005), suggesting a role of co-transmitter modulating postsynaptic GABA receptors. On the other hand, GAA can activate GABA<sub>A</sub> receptors in cortical and cerebellar neurons (Neu et al., 2002; Cupello et al., 2008). In cortex in particular, GAA can activate GABA<sub>A</sub> receptors at concentrations compatible with its levels in CNS extracellular fluid (see above; and Neu et al., 2002; Braissant and Henry, 2008). Thus, both Cr and GAA can act as neuromodulators. Keeping AGAT and GAMT expression separated in different brain cells might thus facilitate the fine tuning of the respective synthesis of GAA and Cr for their specific roles of neuromodulation, while the efficient uptake of Cr and GAA by brain cells might be essential for keeping their extracellular concentrations in low ranges, to allow neuro-modulation (Cr and GAA) while avoiding toxic effects of GAA.

#### *Fine tuning versus high flux of Cr synthesis and transport in the brain*

Two strikingly coherent main expression patterns are found in the different brain structures. In 1st one, present in most brain regions, high proportions of cells do not express either AGAT, GAMT or SLC6A8 (20–50%), the proportion of cells expressing SLC6A8 only (Cr “users”) remains below 15%, while AGAT and GAMT are not co-expressed. These structures, distributed throughout the whole CNS, may need the dissociation between AGAT and GAMT expression, as well as the low proportion of cells expressing SLC6A8, for the fine tuning of GAA and Cr synthesis described above, and their respective roles in neuromodulation.

In 2nd one, specific structures (hippocampus, Purkinje neurons) present high proportions of cells co-expressing AGAT + GAMT (40–60%), and high proportions of cells expressing SLC6A8 (45–65%). It suggests that these neuronal layers permanently need high Cr levels, in line with their high creatine kinase activity (Wallimann and Hemmer, 1994; Kaldis et al., 1996).

#### *Neuronal versus glial synthesis of creatine*

While GAMT is expressed by rat neurons and glia (Braissant et al., 2001a), data showing GAMT predominantly (but not exclusively) in mouse glia (Schmidt et al., 2004; Tachikawa et al., 2004) suggested that Cr synthesis final step may principally be glial. Brain mixed-cell or astrocyte primary cultures synthesize Cr (Dringen et al., 1998; Braissant et al., 2008), but we also showed that neuron-enriched primary cultures synthesize Cr (Braissant et al., 2002). This study demonstrates that depending on brain structure, Cr synthesis may occur both in neurons and glia. In cortex, 48% of NeuN-positive neurons and 21% of GFAP-positive astrocytes expressed GAMT. CA3, dentate gyrus and Purkinje neurons were 50%–70% to express GAMT. Both neurons and astrocytes presented every possibility of AGAT, GAMT and SLC6A8 co-expression patterns (apart of SLC6A8 absence from astrocytes), and both neurons and astrocytes could be silent for the three genes. It is emphasized that oligodendrocytes, not evaluated in this study, highly express GAMT (Schmidt et al., 2004; Tachikawa et al., 2004; Braissant et al., 2008), and may be high Cr producers. It remains also to elucidate how Cr can leave “Cr producers” to be taken up by “Cr users” through SLC6A8.

#### *Conclusion*

We show that in numerous rat brain structures, including cortex and caudate putamen, AGAT and GAMT are expressed in a dissociated way, suggesting GAA transport from AGAT- to GAMT-expressing cells to allow Cr synthesis. Accordingly, this work is the first to demonstrate that brain cells can take up GAA probably through SLC6A8, and convert it to Cr. Taken together, our results explain the absence of Cr in the brain of SLC6A8-deficient patients, despite normal AGAT and GAMT expression.

#### *Acknowledgments*

We thank Marc Loup for excellent technical work. This work was supported by the Swiss National Science Foundation (grant numbers 3100A0-100778 and 3100A0-116859).

#### *Appendix A. Supplementary data*

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.nbd.2009.10.022](https://doi.org/10.1016/j.nbd.2009.10.022).

#### *References*

- Almeida, L.S., Salomons, G.S., Hogenboom, F., Jakobs, C., Schoffeleer, A.N., 2006. Exocytotic release of creatine in rat brain. *Synapse* 60, 118–123.
- Andres, R.H., Ducray, A.D., Schlattner, U., Wallimann, T., Widmer, H.R., 2008. Functions and effects of creatine in the central nervous system. *Brain Res. Bull.* 76, 329–343.
- Braissant, O., 2004. Measurement of nitric oxide-related enzymes in the brain by *in situ* hybridization. *Methods Mol. Biol.* 279, 113–124.
- Braissant, O., Henry, H., 2008. AGAT, GAMT and SLC6A8 distribution in the central nervous system, in relation to creatine deficiency syndromes: A review. *J. Inher. Metab. Dis.* 31, 230–239.
- Braissant, O., Henry, H., Loup, M., Eilers, B., Bachmann, C., 2001a. Endogenous synthesis and transport of creatine in the rat brain: an *in situ* hybridization study. *Mol. Brain Res.* 86, 193–201.
- Braissant, O., Gotoh, T., Loup, M., Mori, M., Bachmann, C., 2001b. Differential expression of the cationic amino acid transporter 2(B) in the adult rat brain. *Mol. Brain Res.* 91, 189–195.
- Braissant, O., Henry, H., Villard, A.M., Zurich, M.G., Loup, M., Eilers, B., Parlascino, G., Matter, E., Boulard, O., Honegger, P., Bachmann, C., 2002. Ammonium-induced impairment of axonal growth is prevented through glial creatine. *J. Neurosci.* 22, 9810–9820.
- Braissant, O., Henry, H., Villard, A.M., Speer, O., Wallimann, T., Bachmann, C., 2005. Creatine synthesis and transport during rat embryogenesis: spatiotemporal expression of AGAT, GAMT and CT1. *BMC Dev. Biol.* 5, 9.
- Braissant, O., Bachmann, C., Henry, H., 2007. Expression and function of AGAT, GAMT and CT1 in the mammalian brain. *Sub-cell. Biochem.* 46, 67–81.
- Braissant, O., Cagnon, L., Monnet-Tschudi, F., Speer, O., Wallimann, T., Honegger, P., Henry, H., 2008. Ammonium alters creatine transport and synthesis in a 3D-culture of developing brain cells, resulting in secondary cerebral creatine deficiency. *Eur. J. Neurosci.* 27, 1673–1685.
- Cagnon, L., Braissant, O., 2007. Hyperammonemia-induced toxicity for the developing central nervous system. *Brain Res. Rev.* 56, 183–197.
- Cupello, A., Balestrino, M., Gatta, E., Pellistri, F., Siano, S., Robello, M., 2008. Activation of cerebellar granule cells GABA(A) receptors by guanidinoacetate. *Neuroscience* 152, 65–69.
- DeGrauw, T.J., Salomons, G.S., Cecil, K.M., Chuck, G., Newmeyer, A., Schapiro, M.B., Jakobs, C., 2002. Congenital creatine transporter deficiency. *Neuropediatrics* 33, 232–238.
- Dringen, R., Verleysdonk, S., Hamprecht, B., Willker, W., Leibfritz, D., Brand, A., 1998. Metabolism of glycine in primary astroglial cells: synthesis of creatine, serine, and glutathione. *J. Neurochem.* 70, 835–840.
- Fons, C., Sempere, A., Arias, A., López-Sala, A., Póo, P., Pineda, M., Mas, A., Vilaseca, M.A., Salomons, G.S., Ribes, A., Artuch, R., Campistol, J., 2008. Arginine supplementation in four patients with X-linked creatine transporter defect. *J. Inher. Metab. Dis.* 31, 724–728.
- Honegger, P., Monnet-Tschudi, F., 2001. Aggregating neural cell culture. In: Fedoroff, S., Richardson, A. (Eds.), *Protocols for neural cell culture*. Humana Press Inc., Totowa NJ, pp. 199–218.
- Item, C.B., Stöckler-Ipsiroglu, S., Stromberger, C., Mühl, A., Alessandri, M.G., Bianchi, M.C., Tosetti, M., Fornai, F., Cioni, G., 2001. Arginine:glycine amidinotransferase deficiency: the third inborn error of creatine metabolism in humans. *Am. J. Hum. Genet.* 69, 1127–1133.
- Kaldis, P., Hemmer, W., Zanolli, E., Holtzman, D., Wallimann, T., 1996. ‘Hot spots’ of creatine kinase localization in brain: cerebellum, hippocampus and choroid plexus. *Dev. Neurosci.* 18, 542–554.

- Koga, Y., Takahashi, H., Oikawa, D., Tachibana, T., Denbow, D.M., Furuse, M., 2005. Brain creatine functions to attenuate acute stress responses through GABAergic system in chicks. *Neuroscience* 132, 65–71.
- McGuire, D.M., Gross, M.D., Van Pilsom, J.F., Towle, H.C., 1984. Repression of rat kidney L-arginine:glycine amidinotransferase synthesis by creatine at a pretranslational level. *J. Biol. Chem.* 259, 12034–12038.
- Nedergaard, M., Ransom, B., Goldman, S.A., 2003. New roles for astrocytes: redefining the functional architecture of the brain. *Trends Neurosci.* 26, 523–530.
- Neu, A., Neuheff, H., Trube, G., Fehr, S., Ullrich, K., Roeper, J., Isbrandt, D., 2002. Activation of GABA(A) receptors by guanidinoacetate: a novel pathophysiological mechanism. *Neurobiol. Dis.* 11, 298–307.
- Ohtsuki, S., Tachikawa, M., Takanaga, H., Shimizu, H., Watanabe, M., Hosoya, K., Terasaki, T., 2002. The blood–brain barrier creatine transporter is a major pathway for supplying creatine to the brain. *J. Cereb. Blood Flow Metab.* 22, 1327–1335.
- Paxinos, G., Watson, C., 1986. *The rat brain in stereotaxic coordinates*. Academic Press Limited, London.
- Perasso, L., Cupello, A., Lunardi, G.L., Principato, C., Gandolfo, C., Balestrino, M., 2003. Kinetics of creatine in blood and brain after intraperitoneal injection in the rat. *Brain Res.* 974, 37–42.
- Pisano, J.J., Abraham, D., Udenfriend, S., 1963. Biosynthesis and disposition of  $\gamma$ -guanidinobutyric acid in mammalian tissues. *Arch. Biochem. Biophys.* 100, 323–329.
- Renema, W.K., Schmidt, A., van Asten, J.J., Oerlemans, F., Ullrich, K., Wieringa, B., Isbrandt, D., Heerschap, A., 2003. MR spectroscopy of muscle and brain in guanidinoacetate methyltransferase (GAMT)-deficient mice: validation of an animal model to study creatine deficiency. *Magn. Reson. Med.* 50, 936–943.
- Salomons, G.S., van Dooren, S.J., Verhoeven, N.M., Cecil, K.M., Ball, W.S., DeGrauw, T.J., Jakobs, C., 2001. X-linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome. *Am. J. Hum. Genet.* 68, 1497–1500.
- Schmidt, A., Marescau, B., Boehm, E.A., Renema, W.K., Peco, R., Das, A., Steinfeld, R., Chan, S., Wallis, J., Davidoff, M., Ullrich, K., Waldschütz, R., Heerschap, A., De Deyn, P.P., Neubauer, S., Isbrandt, D., 2004. Severely altered guanidino compound levels, disturbed body weight homeostasis and impaired fertility in a mouse model of guanidinoacetate N-methyltransferase (GAMT) deficiency. *Hum. Mol. Genet.* 13, 905–921.
- Schulze, A., Battini, R., 2007. Pre-symptomatic treatment of creatine biosynthesis defects. *Sub-cell. Biochem.* 46, 167–181.
- Schulze, A., Hess, T., Wevers, R., Mayatepek, E., Bachert, P., Marescau, B., Knopp, M.V., De Deyn, P.P., Bremer, H.J., Rating, D., 1997. Creatine deficiency syndrome caused by guanidinoacetate methyltransferase deficiency: diagnostic tools for a new inborn error of metabolism. *J. Pediatr.* 131, 626–631.
- Stöckler, S., Holzbach, U., Hanefeld, F., Marquardt, I., Helms, G., Requate, M., Hänicke, W., Frahm, J., 1994. Creatine deficiency in the brain: a new, treatable inborn error of metabolism. *Pediatr. Res.* 36, 409–413.
- Stöckler, S., Schutz, P.W., Salomons, G.S., 2007. Cerebral creatine deficiency syndromes: clinical aspects, treatment and pathophysiology. *Sub-cell. Biochem.* 46, 149–166.
- Tachikawa, M., Fukaya, M., Terasaki, T., Ohtsuki, S., Watanabe, M., 2004. Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK-Mi and CK-B suggest a novel neuron–glial relationship for brain energy homeostasis. *Eur. J. Neurosci.* 20, 144–160.
- Tachikawa, M., Fujinawa, J., Takahashi, M., Kasai, Y., Fukaya, M., Sakai, K., Yamazaki, M., Tomi, M., Watanabe, M., Sakimura, K., Terasaki, T., Hosoya, K., 2008. Expression and possible role of creatine transporter in the brain and at the blood–cerebrospinal fluid barrier as a transporting protein of guanidinoacetate, an endogenous convulsant. *J. Neurochem.* 107, 768–778.
- Tarnopolsky, M., Parise, G., Fu, M.H., Brose, A., Parshad, A., Speer, O., Wallimann, T., 2003. Acute and moderate-term creatine monohydrate supplementation does not affect creatine transporter mRNA or protein content in either young or elderly humans. *Mol. Cell. Biochem.* 244, 159–166.
- Von Figura, K., Hanefeld, F., Isbrandt, D., Stöckler-Ipsiroglu, S., 2001. Guanidinoacetate methyltransferase deficiency. In: Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D. (Eds.), *The metabolic and molecular bases of inherited disease*. McGraw-Hill, New York, pp. 1897–1908.
- Wallimann, T., Hemmer, W., 1994. Creatine kinase in non-muscle tissues and cells. *Mol. Cell. Biochem.* 133–134, 193–220.
- Wyss, M., Kaddurah-Daouk, R., 2000. Creatine and creatinine metabolism. *Physiol. Rev.* 80, 1107–1213.